Clinical Policy: Bevacizumab (Avastin)

Reference Number: CP.PHAR.93
Effective Date: 12.01.11
Last Review Date: 02.18 Coding Implications
Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

Bevacizumab (Avastin®) is a vascular endothelial growth factor-specific angiogenesis inhibitor.

FDA Approved Indication(s)

Avastin is indicated:

- For the treatment of metastatic colorectal cancer, with intravenous 5-fluorouracil (5-FU)-based chemotherapy for first- or second-line treatment
- For the treatment of metastatic colorectal cancer, with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line Avastin containing regimen
- For the treatment of non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent, or metastatic disease
- For the treatment of glioblastoma, as a single agent for adult patients with progressive disease following prior therapy
  - Effectiveness is based on improvement in objective response rate. There are no data available demonstrating improvement in disease-related symptoms or survival with Avastin.
- For the treatment of metastatic renal cell carcinoma in combination with interferon alfa
- For the treatment of cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.
- For the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that is
  - Platinum-resistant in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan,
  - Platinum-sensitive in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent

Limitation(s) of use: Avastin is not indicated for adjuvant treatment of colon cancer.

Policy/Criteria

Provider must submit documentation (which may include office chart notes and lab results) supporting that member has met all approval criteria

It is the policy of health plans affiliated with Centene Corporation® that Avastin is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. FDA Approved Indications (must meet all):

1. Diagnosis of one of the following:
   a. Colorectal cancer:
   b. Non-squamous non-small cell lung cancer:
   c. Glioblastoma;
   d. Metastatic renal cell carcinoma:
   e. Carcinoma of the cervix:
   f. Epithelial ovarian, fallopian tube, or primary peritoneal cancer;
2. Member meets one of the following:
   a. For colorectal cancer, used in combination with 5-FU based chemotherapy
   b. For non-squamous non-small cell lung cancer, use in combination with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease;
   c. For glioblastoma, patient has progressive disease;
   d. For metastatic renal cell carcinoma, used in combination with interferon alfa;
   e. For cervical cancer, used in combination with paclitaxel and cisplatin or topotecan;
   f. For epithelial ovarian, fallopian tube, or primary peritoneal cancer, disease is persistent, recurrent, or metastatic;
3. Prescribed by or in consultation with an oncologist;
4. Age ≥ 18 years;
5. Request meets one of the following (a or b):
   a. Dose does not exceed 15 mg/kg IV every 3 weeks or 10 mg/kg IV every 2 weeks;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

Approval duration:
Medicaid/Health Insurance Marketplace – 6 months
Commercial – Length of benefit

B. Oncology - Non-FDA Approved Indications (off-label) (must meet all):

1. Diagnosis of one of the following conditions:
   a. Breast cancer;
   b. Endometrial carcinoma;
   c. Malignant pleural mesothelioma;
   d. Primary central nervous system cancers;
   e. Soft tissue sarcoma;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

Approval duration:
Medicaid/Health Insurance Marketplace – 6 months
Commercial – Length of benefit

C. Ophthalmology - Non-FDA Approved Indications (off-label) (must meet all):

1. Diagnosis of one of the following conditions:
   a. Neovascular (wet) age-related macular degeneration;
   b. Macular edema following retinal vein occlusion;
   c. Diabetic macular edema;
   d. Proliferative diabetic retinopathy;
   e. Neovascular glaucoma;
   f. Choroidal neovascularization associated with: angioid streaks, no known cause, inflammatory conditions, high pathologic myopia, or ocular histoplasmosis syndrome;
   g. Diabetic retinopathy associated with ocular neovascularization (choroidal, retinal, iris);
2. Age ≥ 18 years;
3. Request meets one of the following (a or b):
   a. Dose does not exceed 2.5 mg/dose;
   b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

Approval Duration:
Medicaid/Health Insurance Marketplace – 6 months
Commercial – Length of benefit

D. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all)**:**

1. Member meets one of the following (a or b):
   a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   b. Documentation supports that member is currently receiving Avastin for an oncology indication listed in section I and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):
   a. New dose does not exceed 15 mg/kg IV every 3 weeks or 10 mg/kg IV every 2 weeks;
   b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

Approval duration:
Medicaid/Health Insurance Marketplace – 12 months
Commercial – Length of benefit

B. Other diagnoses/indications (must meet 1 or 2)**:**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.
   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

5-FU: fluorouracil
5-FU/LV: fluorouracil, leucovorin
CapeOX: capecitabine, oxaliplatin
FDA: Food and Drug Administration
FOLFIRI: fluorouracil, leucovorin, irinotecan
FOLFOX: fluorouracil, leucovorin, oxaliplatin
FOLFOXIRI: fluorouracil, leucovorin, oxaliplatin, irinotecan
NCCN: National Comprehensive Cancer Network

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Metastatic carcinoma of the colon or rectum		
FOLFOX4 = Infusional 5-FU/leucovorin/ oxaliplatin	Oxaliplatin 85 mg/m^2 IV over 2 hours day 1; leucovorin 200 mg/m^2 IV over 2 hours days 1 & 2, followed by 5-FU 400 mg/m^2 IV bolus over 2-4 minutes, followed by 600 mg/m^2 IV 5-FU continuous infusion over 22 hours on days 1 & 2. Repeat cycle every 14 days.	varies
FOLFIRI = Infusional 5-FU/ leucovorin/Camptosar® (irinotecan)	Camptosar 180 mg/m^2 IV over 90 minutes day 1; Leucovorin 400 mg/m^2 IV over 2 hours day 1 followed by 5-FU 400 mg/m^2 IV bolus over 2-4 minutes, followed by 2.4 gm/m^2 IV 5-FU continuous infusion over 46 hours. Repeat cycle every 14 days.	varies

capecitabine (Xeloda®)	2500 mg/m^2 PO BID for 2 weeks; repeat cycles of 2 weeks on and 1 week off. For patients who cannot tolerate intensive therapy.	varies
NSCLC		
cisplatin carboplatin paclitaxel docetaxel vinorelbine gemcitabine etoposide irinotecan vinblastine mitomycin ifosfamide pemetrexed disodium (Alimta®) (2nd line)	Various doses	varies
Ovarian Cancer		
carboplatin and paclitaxel	Carboplatin dosed at an area under the curve (AUC) of 5-7.5 and paclitaxel 175 mg/m^2 IV over 3 hours given every 3 weeks for 6 courses.	varies
docetaxel taxotere and carboplatin	Docetaxel, 60-75 mg/m^2 IV over 1 hour plus carboplatin dosed at AUC of 5 to 6 every 3 weeks.	varies
Glioblastoma Multiforme		
temozolomide (Temodar®)	Maintenance phase cycles: 150 mg-200 mg/m² PO days 1-5. Repeat every 28 days.	varies
carmustine (Bincu®)	150 mg to 200 mg/m² IV on day 1. Repeat every 6-8 weeks for one year or tumor progression.	varies
Cervical Cancer		
cisplatin/paclitaxel	Paclitaxel: 135 mg/m^2 IV as a continuous infusion over 24 hours day 1 Cisplatin: 50 mg/m^2 IV on day 2 Repeat cycle every 21 days for up to a total of 6 cycles; responders may continue beyond 6 cycles	varies
cisplatin/topotecan (Hycamtin®)	Topotecan: I0.75 mg/m^2/day IV on days 1, 2, and 3	varies

	Cisplatin: 50 mg/m^2 IV on day 1 only Repeat cycle every 21 days for up to a total of 6 cycles; responders may continue beyond 6 cycles	
topotecan (Hycamtin®)/paclitaxel	Paclitaxel: 135 mg/m^2 IV continuous infusion over 24 hours day 1 Topotecan: 0.75 mg/m^2/day IV on days 1, 2, and 3 Repeat cycle every 21 days for up to a total of 6 cycles; responders may continue beyond 6 cycles	varies

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: General Information

- The FDA revoked the approval of the breast cancer indication for Avastin (bevacizumab) on November 18, 2011. Avastin used for metastatic breast cancer has not been shown to provide a benefit, in terms of delay in the growth of tumors that would justify its serious and potentially life-threatening risks. Nor is there evidence that use of Avastin will either help women with breast cancer live longer or improve their quality of life.
- Fatal pulmonary hemorrhage can occur in patients with NSCLC treated with chemotherapy and Avastin. The incidence of severe or fatal hemoptysis was 31% in patients with squamous histology and 2.3% with NSCLC excluding predominant squamous histology. Patients with recent hemoptysis should not receive Avastin.
- Avastin has been added to the National Comprehensive Cancer Network (NCCN) practice guidelines as category 2A for recurrent ovarian cancer for patients who have progressed on two consecutive single-agent regimens without evidence of clinical benefit.
- Age-related macular degeneration, secondary to choroidal neovascularization
  - In a prospective time-series trial, bevacizumab 2.5 mg was administered by intravitreal injection every 4 weeks for a total of 3 injections
  - In one retrospective study, bevacizumab 1.25 mg was administered by intravitreal injection once monthly for a total of three injections.
  - In another retrospective study intravitreal bevacizumab 1.25 mg was administered once monthly until macular edema, subretinal fluid, and/or pigment epithelial detachment resolved (Avery et al, 2006).
- Avastin, with or without irinotecan, has been added to the NCCN practice guidelines for recurrent or salvage therapy of Glioblastoma Multiforme and Anaplastic Astrocytoma, but is considered 2B in combination with carboplatin.
- Avastin is effective for the treatment of neovascular glaucoma that is not responsive to maximal doses of antiglaucoma medications. While most studies did not indicate the agents that were tried and failed prior to the use of Avastin in neovascular glaucoma, one study did indicate the use of timolol, dorzolamide, and brimonidine before an Avastin

injection.

- Avastin is category 2A for the treatment of soft tissue sarcoma-angiosarcoma and soft tissue sarcoma-solitary fibrous tumor/hemangiopericytoma in the NCCN practice guidelines for soft tissue sarcomas.
- Avastin is a category 2A, in the NCCN practice guidelines, for the treatment of adult intracranial and spinal ependymoma (excluding subependymoma).
- Avastin is category 2A, in the NCCN practice guidelines, for the treatment of non-clear cell renal carcinoma.
- Avastin is category 2A, in the NCCN practice guidelines, for the treatment of endometrial carcinoma
- Avastin in combination with cisplatin/paclitaxel has been added to the NCCN practice guidelines as category 1 for recurrent or metastatic cervical cancer. Avastin in combination with topotecan/paclitaxel has been added as a category 2B recommendation for this same indication.
- Avastin is rated category 2A, in the NCCN practice guidelines, for the diagnosis of relapsed or medically unresectable stage IV renal carcinoma following prior cytokine therapy (a rating of 2B is given if following prior tyrosine kinase inhibitor therapy).
- Avastin has a black box warning for gastrointestinal perforation, surgery and wound healing complications, and hemorrhage. Avastin should be discontinued in patients with wound dehiscence. Discontinue at least 28 days prior to elective surgery. Do not initiate Avastin for at least 28 days after surgery and until the surgery wound is fully healed. Avastin causes severe or fatal hemorrhage, hemoptysis, gastrointestinal bleeding, CNS hemorrhage, and vaginal bleeding. Do not administer to patients with serious hemorrhage or recent hemoptysis.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Metastatic Colorectal Cancer	5 mg/kg or 10 mg/kg once every 14 days as an IV infusion in combination with a 5-FU based chemotherapy regimen until disease progression is detected. 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line Avastin-containing regimen	15 mg/kg IV every 3 weeks or 10 mg/kg IV every 2 weeks.
Non-Squamous, Non-Small Cell Lung Cancer	15 mg/kg IV infusion every 3 weeks with carboplatin/paclitaxel	15 mg/kg IV every 3 weeks or 10 mg/kg IV every 2 weeks.
Ovarian Cancer	15 mg/kg IV infusion every 3 weeks	15 mg/kg IV every 3 weeks or 10 mg/kg IV every 2 weeks.

Platinum resistant ovarian cancer	10 mg/kg intravenously every 2 weeks with weekly paclitaxel, liposomal doxorubicin, or topotecan or 15mg/kg every 3 weeks if given with topotecan every 3 weeks.	15 mg/kg IV every 3 weeks or 10 mg/kg IV every 2 weeks.
Clear cell renal carcinoma	10 mg/kg IV every 2 weeks with interferon alfa	15 mg/kg IV every 3 weeks or 10 mg/kg IV every 2 weeks.
Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma	10 mg/kg IV every 2 weeks	15 mg/kg IV every 3 weeks or 10 mg/kg IV every 2 weeks.
Soft tissue sarcoma	15 mg/kg IV infusion every 3 weeks	15 mg/kg IV every 3 weeks or 10 mg/kg IV every 2 weeks.
Cervical Cancer	15 mg/kg IV infusion every 3 weeks (in combination with paclitaxel and either cisplatin or topotecan) until disease progression or unacceptable toxicity	15 mg/kg IV every 3 weeks or 10 mg/kg IV every 2 weeks.
Neovascular (Wet) Macular Degeneration	1.25 to 2.5 mg administered by intravitreal injection every 4 weeks	2.5 mg/dose
Neovascular Glaucoma	1.25 mg administered by intravitreal injection every 4 weeks	2.5 mg/dose
Macular edema secondary to retinal vein occlusion	1 mg to 2.5 mg administered by intravitreal injection every 4 weeks	2.5 mg/dose
Proliferative diabetic retinopathy	1.25 mg administer by intravitreal injection 5 to 20 days before vitrectomy	2.5 mg/dose
Diabetic Macular Edema	1.25 mg administered by intravitreal injection	2.5 mg/dose
Malignant Mesothelioma of Pleura	15 mg/kg IV (plus pemetrexed 500 mg/m(2) IV and cisplatin 75 mg/m(2) IV) every 21 days for up to 6 cycles, followed by maintenance bevacizumab 15 mg/kg every 21 days until disease progression or unacceptable toxicity. All patients should receive folic acid 400 mcg orally daily and vitamin B12 1000 mcg IM every 3 weeks, both beginning 7 days prior to pemetrexed and continuing for 3 weeks following the last pemetrexed dose (off-label dosage).	2.5 mg/dose

Metastatic Colorectal Cancer in Previously Untreated Elderly Patients Ineligible for Oxaliplatin- or Irinotecan-based Chemotherapy	7.5 mg/kg IV on day 1 with capecitabine 1000 mg/m(2) orally twice daily on days 1 to 14, given every 3 weeks until disease progression.	15 mg/kg IV every 3 weeks or 10 mg/kg IV every 2 weeks.

VI. Product Availability

Single-use vials: 100 mg/4 ml, 400 mg/16 ml

VII. References

1. Avastin. Prescribing Information. South San Francisco, CA: Genentech, Inc. December 2016. Available at: www.avastin.com. Accessed November 20, 2017.
2. Bevacizumab. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at NCCN.org. Accessed November 20, 2017.
3. Bevacizumab. In: Micromedex. Ann Arbor, MI: Truven Health Analytics; 2013. Available from: www.micromedexsolutions.com. Accessed November 20, 2017.
4. Bevacizumab. In: Clinical Pharmacology. Tampa, FL: Gold Standard; 2008. Available at www.clinicalpharmacology.com. Accessed November 20, 2017.
5. Bevacizumab. In: Lexicomp. Hudson, OH: Wolters Kluwer; 2016. Available at www.online.lexi.com. Accessed November 20, 2017.
6. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-Related Macular Degeneration. San Francisco, CA: American Academy of Ophthalmology; 2015. Available at www.aao.org/ppp. Accessed November 20, 2017.
7. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2016. Available at www.aao.org/ppp. Accessed November 20, 2017.
8. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Retinal Vein Occlusions. San Francisco, CA: American Academy of Ophthalmology; November 2015. Available at www.aao.org/ppp. Accessed November 20, 2017.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9035	Injection, bevacizumab, 10 mg
C9257	Injection, bevacizumab, 0.25 mg

ICD-10-CM Diagnosis Codes that Support Coverage Criteria

The following is a list of diagnosis codes that support coverage for the applicable covered procedure code(s).

ICD-10-CM Code	Description
A18.53	Tuberculosis chorioretinitis
C17.0 – C17.9	Malignant neoplasm of small intestine
C18.0 – C18.9	Malignant neoplasm of colon
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C34.00 – C34.02	Malignant neoplasm of main bronchus
C34.10 – C34.12	Malignant neoplasm of upper lobe, bronchus or lung
C34.2	Malignant neoplasm of middle lobe, bronchus or lung
C34.30 – C34.32	Malignant neoplasm of lower lobe, bronchus or lung
C34.80 – C34.82	Malignant neoplasm of overlapping sites of bronchus and lung
C34.90 – C34.92	Malignant neoplasm of unspecified part of bronchus or lung
C48.0 – C48.8	Malignant neoplasm of retroperitoneum and peritoneum
C49.0 – C49.9	Malignant neoplasm of other connective and soft tissue
C50.01 – C50.929	Malignant neoplasm of breast
C53.0 – C53.9	Malignant neoplasm of cervix uteri
C54.0 – C55	Malignant neoplasm of corpus uteri
C56.1 – C56.9	Malignant neoplasm of ovary
C57.0 – C57.9	Malignant neoplasm of other and unspecified female genital organs
C64.1 – C64.9	Malignant neoplasm of kidney, except renal pelvis
C65.1 – C65.9	Malignant neoplasm of renal pelvis
C70.0 – C70.9	Malignant neoplasm of meninges
C71.0 – C71.9	Malignant neoplasm of brain
C72.0 – C72.9	Malignant of spinal cord, cranial neoplasm nerves and other parts of central nervous system
E08.311, E08.3211 – E08.3219, E08.3311 – E08.3319, E08.3411 – E08.3419, E08.3511 – E08.3519	Diabetes mellitus due to underlying condition with diabetic retinopathy with macular edema
E09.311, E09.3211 – E09.3219, E09.3311 – E09.3319, E09.3411 – E09.3419, E09.3511 – E093519	Drug or chemical induced diabetes mellitus with diabetic retinopathy with macular edema
E10.311, E10.3211 – E10.3219, E10.3311 – E10.3319, E10.3411 – E10.3419, E10.3511 – E10.3519	Type 1 diabetes mellitus with diabetic retinopathy with macular edema
E11.311, E11.3211 – E11.3219, E11.3311 – E11.3319,	Type 2 diabetes mellitus with diabetic retinopathy with macular edema

ICD-10-CM Code	Description
E11.3411 – E11.3419, E11.3511 – E11.3519	
E13.311, E13.3211 – E13.3219, E13.3311 – E13.3319, E13.3411 – E13.3419, E13.3511 – E13.3519	Other specified diabetes mellitus with diabetic retinopathy with macular edema
H16.401 – H16.449	Corneal neovascularization
H30.001 – H30.049	Focal chorioretinal inflammation
H30.101 – H30.139	Disseminated chorioretinal inflammation
H30.891 – H30.899	Other chorioretinal inflammations
H30.90 – H30.93	Unspecified chorioretinal inflammations
H32	Chorioretinal disorders in diseases classified elsewhere
H34.8110 – H 34.8192	Central retinal vein occlusion
H34.8310 – H34.8392	Tributary (branch) retinal vein occlusion
H35.051 – H35.059	Retinal neovascularization, unspecified
H35.141 – H35.169	Retinopathy of prematurity, stages 3 through 5
H35.3210 – H35.3293	Exudative age-related macular degeneration
H35.33	Angioid streaks of macula
H35.81	Retinal edema
H40.50X0-H40.53X4	Glaucoma secondary to other eye disorders [associated with vascular disorders of eye]
H44.20-H44.23	Degenerative myopia
Z85.038	Personal history of other malignant neoplasm of large intestine
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus
Z85.068	Personal history of other malignant neoplasm of small intestine
Z85.118	Personal history of other malignant neoplasm of bronchus and lung
Z85.3	Personal history of malignant neoplasm of breast
Z85.41	Personal history of malignant neoplasm of cervix uteri
Z85.42	Personal history of malignant neoplasm of other parts of uterus
Z85.43	Personal history of malignant neoplasm of ovary
Z85.44	Personal history of malignant neoplasm of other female genital organs
Z85.528	Personal history of other malignant neoplasm of kidney
Z85.53	Personal history of malignant neoplasm of renal pelvis
Z85.841	Personal history of malignant neoplasm of brain
Z85.848	Personal history of malignant neoplasm of other parts of nervous tissue

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Updated background, safety profile and contraindications	02.14	03.14
Added cervical cancer indication	11.14	11.14

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Updated criteria per NCC guidelines for monotherapy or combination therapy and first line or maintenance therapy		
Converted criteria into bullet points and changed to new policy template Edited FDA-approved indications in section I to correspond to PI – all indications are limited to adults; added ovarian cancer; Limited compendial indications to cancer type – all compendial indications are in section II Added HCPCS and ICD-10 codes Policy arranged in disease specific criteria sets Added ocular indications as previously approved from CP.PHAR.38	10.15	11.15
CP.PHAR.93.Avastin policy converted to new template; incorporates Avastin content from CP.PHAR.39 AMD Retinal Disorder Treatments. Added age and max dose; monotherapy defined as "other anti-VEGF drugs;" removed requests for documentation. References: removed 2008 Genentech letter regarding infections correlating with Avastin intravitreal use as it is no longer available.	03.16	09.16
Updated coding. Updated disclaimer language.	09.16	09.16
New FDA labeled indication added: Platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer. Doses removed. Under renal cell carcinoma, FDA approved use, added 2a/2b subtypes to interferon alpha. Safety criteria limited to black box warnings precluding initiation of therapy.Off-label ocular use is edited to follow supported uses in Micromedex and Clinical Pharmacology (i.e., AMD secondary to choroidal neovascularization, macular edema secondary to branch/central retinal vein occlusion or diabetes, choroidal retinal neovascularization secondary to pathologic myopia or angioid streaks, diabetic retinopathy, retinopathy of prematurity). Choroidal neovascularization associated with no known cause or with inflammation or ocular histoplasmosis syndrome is removed but may be requested under the Global Biopharm policy. Approval duration lengthened to 6 and 12 months. Added ICD-10 appropriate code ranges for eye conditions that now have a new 6th or 7th digit indicating the specific eye.	03.17	04.17
1Q18 annual review: - Policies combined from Medicaid and commercial	11.20.17	02.18

Reviews, Revisions, and Approvals	Date	P&T Approval Date
- Specialist involvement in care added to all indications - Added specific criteria for off-label uses for ophthalmic indications - Added allowable off-label oncology indications as reflected in the NCCN compendium - References reviewed and updated		

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:
For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

For Health Insurance Marketplace members, when applicable, this policy applies only when the prescribed agent is on your health plan approved formulary. Request for non-formulary drugs must be reviewed using the formulary exception policy.